How many clinical trials are running for atogepant?

ClinicalTrials.gov lists more than 16 phase 2–4 atogepant trials. This page tracks the 16 largest by enrolment: 1 phase 2, 13 phase 3, and 2 phase 4 among them, with 3 actively recruiting. Updated daily.

Where does this data come from?

All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.

Can I compare atogepant against other drugs?

Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.

Neuroscience · Live ClinicalTrials.gov data

Atogepant (Qulipta) clinical trial pipeline

The timeline below tracks the 16 largest phase 2–4 atogepant trials on ClinicalTrials.gov by enrolment, 3 of them actively recruiting. The next phase 3 primary completion among them is expected Feb 2027. Refreshed daily — add up to four competitors to compare pipelines side by side.

16+

Major trials tracked

Phase 3 trials

Actively recruiting

Feb 2027

Next phase 3 primary completion

10,817

Participants across trials

AbbVie

Lead sponsor by trial count

atogepant (16)6 active2016–2034

Hide completed

atogepant

Key

Actual date

Anticipated

Forecast to primary completion

RecruitingActive, not recruitingEnrolling by invitationCompleted

'16

'18

'20

'22

'24

'26

'28

'30

'32

'34

atogepant

Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine PreventionP2

Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic MigraineP3

12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic MigraineP3

Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic MigraineP3

Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic MigraineP3

A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic MigraineP3

ELEVATEP3

TANDEMP4

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic MigraineP3

KaleidoscopeP3

JPN PIVOTALP3

ATO-TOPIRAMATEP3

ATO ACUTEP3

ATO MMP3

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 YearsP3

Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison StudyP4

Upcoming readouts

5 ahead · atogepant

Select a trial to load its full ClinicalTrials.gov record.

Key atogepant trials

Top 12 of the 16 tracked phase 2–4 trials, ordered by phase and status. Each links to its full ClinicalTrials.gov record.

Trial	Title	Phase	Status	Primary completion
NCT06972056	Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study	Phase 4	Recruiting	Mar 2029
NCT05264129	TANDEM — Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat…	Phase 4	Completed	Apr 2023
NCT05711394	A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Par…	Phase 3	Recruiting	Mar 2028
NCT06810505	A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine …	Phase 3	Recruiting	Mar 2031
NCT06241313	ATO ACUTE — Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine	Phase 3	Active, not recruiting	Jul 2025
NCT06806293	ATO MM — Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Men…	Phase 3	Active, not recruiting	Feb 2027
NCT05707949	Kaleidoscope — Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 1…	Phase 3	Enrolling by invitation	Apr 2032
NCT03700320	Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Mi…	Phase 3	Completed	May 2020
NCT03777059	12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Ep…	Phase 3	Completed	Jun 2020
NCT03939312	Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migr…	Phase 3	Completed	Mar 2021
NCT03855137	Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine	Phase 3	Completed	Jan 2022
NCT04740827	ELEVATE — Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.	Phase 3	Completed	Aug 2022

Compare atogepant vs lecanemab Compare atogepant vs donanemab

FAQ

How many clinical trials are running for atogepant?: ClinicalTrials.gov lists more than 16 phase 2–4 atogepant trials. This page tracks the 16 largest by enrolment: 1 phase 2, 13 phase 3, and 2 phase 4 among them, with 3 actively recruiting. Updated daily.
Where does this data come from?: All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.
Can I compare atogepant against other drugs?: Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.

Join the waitlist

Be the first to access ComplyRx

We'll let you know as soon as your spot opens to use ComplyRx.

By joining, you agree to our Privacy Policy.

Upcoming readouts

Key atogepant trials

Related drug pipelines

FAQ

Be the first to access ComplyRx